Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference

Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on October 5, 2021, at 9:30 a.m. ET. A live webcast will be available on the company's website for 90 days post-event. Atea focuses on developing oral therapies for life-threatening viral infections, including SARS-CoV-2, dengue virus, HCV, and RSV, utilizing its proprietary nucleotide prodrug platform to address unmet medical needs.

BOSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on Tuesday, October 5, 2021 at 9:30 a.m. ET.

A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com

FAQ

What is the date and time of Atea Pharmaceuticals' fireside chat at the Guggenheim conference?

The fireside chat is scheduled for October 5, 2021, at 9:30 a.m. ET.

Where can I watch the live webcast of Atea Pharmaceuticals' presentation?

The live webcast can be accessed on Atea Pharmaceuticals' website and will be available for 90 days after the event.

What is Atea Pharmaceuticals focused on developing?

Atea Pharmaceuticals focuses on oral therapies for life-threatening viral infections, including treatments for COVID-19, dengue, hepatitis C, and RSV.

Who is participating in the fireside chat at the Guggenheim conference?

CEO Jean-Pierre Sommadossi and other members of the Atea management team will participate in the fireside chat.

What is the main goal of Atea Pharmaceuticals?

Atea Pharmaceuticals aims to discover, develop, and commercialize oral therapies for unmet medical needs in viral disease treatment.